CellsBin® Inc.

CellsBin is a precision medicine tech-bio company leveraging AI and nanophotonics to precisely identify and characterize rare cells with unmatched sensitivity and scalability, advancing the development and efficacy of cell-based therapies. The CellsBin™ family of products is designed to evaluate the persistence and functional efficacy of therapy cells, as well as their impact on tumor burden, through simple blood tests, eliminating the need for invasive biopsies. Our recently launched product, CB-Scout™, monitors the persistence and functional efficacy of CAR-T and CAR-NK cells at concentrations as low as 1 in 10,000,000 (one thousand times more sensitive than flow cytometry) while providing functional insights beyond the reach of molecular methods like PCR. Coming next is CB™-Insight, designed to assess cell therapy efficacy by directly measuring tumor burden in blood.